China's national scientific research facilities are increasingly accessible to pharmaceutical and materials science industries, enabling advanced molecular analysis and structural characterization. Companies leverage these cutting-edge infrastructure resources to optimize drug development processes, battery performance, and catalyst efficiency at the atomic scale. This collaborative approach between public research institutions and private enterprises accelerates innovation cycles while maximizing the return on investment in sophisticated laboratory equipment and specialized expertise.

Summary auto-generated by AI from the original publisher's content. Editorial standards.